Evidence map›Paper›PMID 34696220›Full record

ArticleVaccines2021

COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series.

Zhe Ruan, Yonglan Tang, Chunhong Li, Chao Sun, Ying Zhu, Zhuyi Li, Ting Chang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Safety and neutralization antibody levels of inactivated SARS-CoV-2 vaccine in adult patients with Myasthenia Gravis: a prospective observational cohort study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Observational
  5. Article
  6. An observational study on the safety of COVID-19 vaccination in patients with myasthenia gravis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Observational
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zhe RuanDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an 710038, China.
Yonglan TangDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an 710038, China.
Chunhong LiDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an 710038, China.
Chao SunDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an 710038, China.
Ying ZhuDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an 710038, China.
Zhuyi LiDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an 710038, China.
Ting ChangDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an 710038, China.
Air Force Medical University · CNTang Du Hospital · CN

Funding

Discipline innovation and development plan of Tangdu Hospital-major clinical research projects 2021LCYJ002
6 · The paper itself

Abstract

In this study, we report the safety of coronavirus disease 2019 (COVID-19) vaccine in patients with myasthenia gravis (MG). Patients who were vaccinated against COVID-19 were included. Demographics, clinical characteristics, medications, and vaccination information were collected. The main observation outcome is the worsening of MG symptoms within 4 weeks following COVID-19 vaccination. A total of 22 patients with MG vaccinated for COVID-19 were included. Ten (45.5%) patients had ocular MG (OMG), and 12 (55.5%) patients had generalized MG (GMG). Six (27.3%) patients were female, and the mean (SD) onset age was 45.4 (11.8) years. Nineteen (86.4%) patients were seropositive for acetylcholine receptors (AChR) antibody. Seven (31.8%) patients underwent thymectomy, and four of them confirmed thymoma pathologically. Twenty-one patients were administrated with inactivated vaccines, and the remaining one was administrated with recombinant subunit vaccine. Twenty (90.9%) patients did not present MG symptom worsening within 4 weeks of COVID-19 vaccination, and two (9.1%) patients reported slight symptom worsening but resolved quickly within a few days. Our findings suggest inactivated COVID-19 vaccines might be safe in MG patients with Myasthenia Gravis Foundation of America (MGFA) classification I to II, supporting the recommendation to promote vaccination for MG patients during the still expanding COVID-19 pandemic.

Indexed as

COVID-19myasthenia gravissafetySARS-CoV-2 infectionvaccination

Identifiers

PMID34696220
PMCPMC8537454
OpenAlexW3202481144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.